Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Glucotrack (GCTK) EBITDA (2016 - 2020)

Glucotrack's EBITDA history spans 7 years, with the latest figure at -$964000.0 for Q4 2020.

  • For the quarter ending Q4 2020, EBITDA fell 114.82% year-over-year to -$964000.0, compared with a TTM value of -$2.8 million through Dec 2020, down 178.88%, and an annual FY2025 reading of -$19.3 million, up 14.33% over the prior year.
  • EBITDA for Q4 2020 was -$964000.0 at Glucotrack, down from -$527000.0 in the prior quarter.
  • The five-year high for EBITDA was $17.9 million in Q4 2017, with the low at -$2.6 million in Q3 2017.
  • Average EBITDA over 5 years is $380433.4, with a median of -$1.0 million recorded in 2019.
  • Year-over-year, EBITDA surged 1647.91% in 2017 and then tumbled 157.31% in 2019.
  • Tracing GCTK's EBITDA over 5 years: stood at -$1.2 million in 2016, then surged by 1647.91% to $17.9 million in 2017, then crashed by 107.37% to -$1.3 million in 2018, then surged by 592.99% to $6.5 million in 2019, then tumbled by 114.82% to -$964000.0 in 2020.
  • Per Business Quant, the three most recent readings for GCTK's EBITDA are -$964000.0 (Q4 2020), -$527000.0 (Q3 2020), and -$599000.0 (Q2 2020).